Hemab Therapeutics closed a $157 million financing to advance multiple programs for bleeding disorders, including a pivotal trial planned for sutacimig in Glanzmann thrombasthenia and an early‑stage HMB‑002 program that has shown proof of mechanism. The round was led by Sofinnova Partners and included crossover and strategic investors. Hemab said proceeds will bankroll pivotal and early clinical activities and additional R&D to build an integrated coagulation franchise addressing understudied bleeding diseases like Von Willebrand and Factor VII deficiency. The company framed its strategy as tackling smaller markets that have historically attracted less commercial investment. The financing reflects renewed investor interest in specialty hematology and the potential upside in developing safer, longer‑lasting alternatives to factor replacement therapies.